{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:45:40Z","timestamp":1790484340974,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.4158\/ep12059.ra","type":"journal-article","created":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T00:56:07Z","timestamp":1354064167000},"page":"120-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Secondary Causes of Osteoporosis"],"prefix":"10.1016","volume":"19","author":[{"given":"Susan M.","family":"DeLange Hudec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline M.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP12059.RA_bb0010","first-page":"3431","article-title":"Osteoporosis in men","volume":"84","author":"Bilezikian","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0015","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.4158\/EP12059.RA_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0889-8529(05)70008-6","article-title":"Secondary osteoporosis: diagnostic considerations","volume":"27","author":"Harper","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4158\/EP12059.RA_rf0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0889-8529(02)00062-2","article-title":"Secondary osteoporosis","volume":"32","author":"Stein","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4158\/EP12059.RA_rf0030","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2002-020275","article-title":"Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women","volume":"87","author":"Tannenbaum","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.16.S3.1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis","volume":"16 (Suppl 3)","author":"Watts","year":"2010","journal-title":"Endocr Pract"},{"key":"10.4158\/EP12059.RA_bb0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0889-8529(02)00087-7","article-title":"The role of estrogens in men and androgens in women","volume":"32","author":"Khosla","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4158\/EP12059.RA_bb0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1210\/jc.2003-031110","article-title":"Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone","volume":"89","author":"Amory","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0045","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1210\/jcem.87.7.8637","article-title":"Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: A longitudinal study","volume":"87","author":"Warren","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0050","doi-asserted-by":"crossref","first-page":"790","DOI":"10.7326\/0003-4819-133-10-200011210-00011","article-title":"Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa","volume":"133","author":"Grinspoon","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP12059.RA_bb0055","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00007256-200030040-00004","article-title":"The physiology of the highly trained female endurance runner","volume":"30","author":"Burrows","year":"2000","journal-title":"Sports Med"},{"key":"10.4158\/EP12059.RA_bb0060","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1210\/jc.2001-011889","article-title":"Abnormal bone mineral accrual in adolescent girls with anorexia nervosa","volume":"87","author":"Soyka","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0065","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00198-009-1120-x","article-title":"Anorexia nervosa, osteoporosis and circulating leptin: the missing link","volume":"21","author":"Legroux","year":"2010","journal-title":"Osteo International"},{"key":"10.4158\/EP12059.RA_bb0070","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/jbmr.5650071215","article-title":"Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise","volume":"7","author":"Seeman","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP12059.RA_bb0075","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1210\/jc.2011-0380","article-title":"Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: A randomized, placebo-controlled study","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0080","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women","volume":"170","author":"Gray","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP12059.RA_bb0085","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s001980070062","article-title":"Drug-induced bone loss","volume":"11","author":"Tannirandorn","year":"2000","journal-title":"Osteoporosis Int"},{"key":"10.4158\/EP12059.RA_bb0090","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.0013-9580.2004.18804.x","article-title":"Fracture risk associated with use of epileptic drugs","volume":"45","author":"Vestergaard","year":"2004","journal-title":"Epilepsia"},{"key":"10.4158\/EP12059.RA_bb0095","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V88.4.1314.bloodjournal8841314","article-title":"Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo","volume":"88","author":"Muir","year":"1996","journal-title":"Blood"},{"key":"10.4158\/EP12059.RA_bb0100","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/0002-9378(93)90378-V","article-title":"Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 1894 women undergoing thromboprophylaxis with heparin","volume":"168","author":"Dahlman","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"10.4158\/EP12059.RA_bb0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0889-8529(02)00064-6","article-title":"Glucocorticoid-induced osteoporosis","volume":"32","author":"Saag","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4158\/EP12059.RA_bb0110","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP12059.RA_bb0115","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-112-5-352","article-title":"Glucocorticoid-induced osteoporosis: pathogenesis and management","volume":"112","author":"Lukert","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP12059.RA_bb0120","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/jcem.83.3.4621","article-title":"Corticosteroid-induced bone loss in men","volume":"801","author":"Pearce","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0125","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"The Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"N Eng J Med"},{"key":"10.4158\/EP12059.RA_bb0130","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.4158\/EP12059.RA_bb0135","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicenter, double-blind, double-dummy, randomized controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.4158\/EP12059.RA_bb0140","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12059.RA_bb0145","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.4158\/EP12059.RA_bb0150","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/jbmr.362","article-title":"Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"26","author":"Hansen","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP12059.RA_bb0155","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP12059.RA_bb0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12059.RA_bb0165","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Int Med"},{"key":"10.4158\/EP12059.RA_bb0170","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP12059.RA_bb0175","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12059.RA_bb0180","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.juro.2010.04.068","article-title":"Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: A matched cohort study of 19,079 men","volume":"184","author":"Alibhai","year":"2010","journal-title":"J Urol"},{"key":"10.4158\/EP12059.RA_bb0185","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"10.4158\/EP12059.RA_bb0190","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP12059.RA_bb0195","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"10.4158\/EP12059.RA_bb0200","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP12059.RA_bb0205","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP12059.RA_bb0210","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1210\/jc.2010-0032","article-title":"Use of repot medroxyprogesterone acetate and gracture risk","volume":"95","author":"Meier","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11914-010-0037-9","article-title":"Oral Contraceptive Use and Bone","volume":"9","author":"Wei","year":"2011","journal-title":"Curr Osteoporos Rep"},{"key":"10.4158\/EP12059.RA_bb0220","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2265.1997.2261041.x","article-title":"Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: Influence of aetiology and menopause","volume":"47","author":"J\u00d3dar","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP12059.RA_bb0225","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4) and thyroid antibodies in the United States population (1988-1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0230","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archinte.160.4.526","article-title":"The Colorado thyroid disease prevalence study","volume":"160","author":"Canaris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP12059.RA_bb0235","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1210\/jc.2010-2693","article-title":"The thyroid epidemiology, audit, and research study (TEARS): Morbidity in patients with endogenous subclinical hyperthyroidism","volume":"96","author":"Vadiveloo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0240","first-page":"4157","article-title":"Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism","volume":"85","author":"Kumeda","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0245","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2004-2364","article-title":"Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy","volume":"90","author":"Holick","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0250","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/edrv.22.4.0437","article-title":"Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications","volume":"22","author":"Lips","year":"2001","journal-title":"Endocr Rev"},{"key":"10.4158\/EP12059.RA_bb0255","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1210\/jcem.86.3.7327","article-title":"A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from Multiple Outcomes of Raloxifene Evaluation clinical trial","volume":"86","author":"Lips","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0260","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Endocrine Society Task Force. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0265","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0270","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4158\/EP.6.5.385","article-title":"Skeletal effects of primary hyperparathyroidism","volume":"6","author":"Syed","year":"2000","journal-title":"Endocr Pract"},{"key":"10.4158\/EP12059.RA_bb0275","first-page":"184","article-title":"Primary hyperparathyroidism: Pathophysiology and impact on bone","volume":"163","author":"Khan","year":"2000","journal-title":"CMAJ"},{"key":"10.4158\/EP12059.RA_bb0280","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1210\/jc.2002-021370","article-title":"Summary statement from a workshop on asymptomatic primary hyperparathyroidism: A perspective for the 21st century","volume":"87","author":"Bilezikian","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0285","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery","volume":"341","author":"Silverberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12059.RA_bb0290","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/bmj.327.7414.530","article-title":"Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism","volume":"327","author":"Vestergaard","year":"2003","journal-title":"BMJ"},{"key":"10.4158\/EP12059.RA_bb0295","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0002-9343(97)00142-3","article-title":"Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure","volume":"103","author":"Shane","year":"1997","journal-title":"Am J Med"},{"key":"10.4158\/EP12059.RA_bb0300","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00198-003-1426-z","article-title":"Osteoporosis after solid organ and bone marrow transplantation","volume":"14","author":"Cohen","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP12059.RA_bb0305","first-page":"1497","article-title":"Bone loss and turnover after cardiac transplantation","volume":"82","author":"Shane","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12059.RA_bb0310","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(00)03641-2","article-title":"Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study","volume":"357","author":"Leidig-Bruckner","year":"2001","journal-title":"Lancet"},{"key":"10.4158\/EP12059.RA_bb0315","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ecl.2007.07.008","article-title":"Post-transplantation osteoporosis","volume":"36","author":"Stein","year":"2007","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.4158\/EP12059.RA_bb0320","series-title":"Incidence of fracture after cardiac and lung transplantation, a single center experience. In: Program of the 2011 Annual Meeting of ASBMR, September 16-20","author":"Hariman","year":"2011"},{"key":"10.4158\/EP12059.RA_bb0325","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2796.2000.00582.x","article-title":"Altered bone metabolism in inflammatory bowel disease: There is a difference between Crohn's disease and ulcerative colitis","volume":"247","author":"Ardizzone","year":"2000","journal-title":"J Intern Med"},{"key":"10.4158\/EP12059.RA_bb0330","first-page":"112","article-title":"Osteoporosis in a North American adult population with celiac disease","volume":"96","author":"Meyer","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.4158\/EP12059.RA_bb0335","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/archinte.165.4.393","article-title":"Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis","volume":"165","author":"Stenson","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP12059.RA_bb0340","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00004836-200403000-00005","article-title":"Metabolic bone disease in inflammatory bowel disease","volume":"38","author":"Harpavat","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.4158\/EP12059.RA_bb0345","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/gut.37.1.71","article-title":"A controlled study of bone mineral density in patients with inflammatory bowel disease","volume":"37","author":"Silvennoinen","year":"1995","journal-title":"Gut"},{"key":"10.4158\/EP12059.RA_bb0350","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-010-1007-0","article-title":"Endocrine and. bone disease in appropriately treated adult patients with beta-thalassemia major","volume":"89","author":"Baldini","year":"2010","journal-title":"Ann Hematol"},{"key":"10.4158\/EP12059.RA_bb0355","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: A population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP12059.RA_bb0360","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study","volume":"116","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.4158\/EP12059.RA_bb0365","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00223-004-0270-2","article-title":"Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women","volume":"77","author":"Reynolds","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"10.4158\/EP12059.RA_bb0370","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1365-2265.2003.01676.x","article-title":"Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas?","volume":"58","author":"Hadjidakis","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP12059.RA_bb0375","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-147-8-200710160-00006","article-title":"Subclinical hypercortisolism among outpatients referred for osteoporosis","volume":"147","author":"Chiodini","year":"2007","journal-title":"Ann Int Med"},{"key":"10.4158\/EP12059.RA_bb0380","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0002-9343(99)80080-1","article-title":"Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol","volume":"98","author":"Levy","year":"1995","journal-title":"Am J Med"},{"key":"10.4158\/EP12059.RA_bb0385","doi-asserted-by":"crossref","first-page":"c89","DOI":"10.1159\/000072491","article-title":"Bone mineral density in girls and their mothers with idiopathic hypercalciuria","volume":"94","author":"Garc\u00eda-Nieto","year":"2003","journal-title":"Nephron Clin Pract"},{"key":"10.4158\/EP12059.RA_bb0390","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0090-4295(02)01626-6","article-title":"Bone alterations in patients with idiopathic hypercalciuria and calcium nephrolithiasis","volume":"59","author":"Tasca","year":"2002","journal-title":"Urology"},{"key":"10.4158\/EP12059.RA_bb0395","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5414\/CNP57183","article-title":"Bone involvement in idiopathic hypercalciuria","volume":"57","author":"Misael da Silva","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.4158\/EP12059.RA_bb0400","doi-asserted-by":"crossref","first-page":"476","DOI":"10.7326\/0003-4819-139-6-200309160-00010","article-title":"Thiazide diuretics and the risk for hip fracture","volume":"139","author":"Mariette","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP12059.RA_bb0405","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00223-004-0084-2","article-title":"Reduced fracture risk in users of thiazide diuretics","volume":"76","author":"Rejnmark","year":"2005","journal-title":"Calcif Tissue Int"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20412121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20412121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/N64428576P856G15.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:55:30Z","timestamp":1761515730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20412121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1530891X20412121"],"URL":"https:\/\/doi.org\/10.4158\/ep12059.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary Causes of Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP12059.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}